Research Priority | Rationale |
---|---|
Observational evidence on the frequency of harms (in particular serious AEs/serious disease flares) in people with ARDs | If very infrequent, may lower the importance of these outcomes |
Evidence comparing the frequency of serious AEs and autoimmune AEs in people with ARDs to those without ARDs | If not different with sufficient certainty, the panel may decide not to rate the quality of evidence for harms down for indirectness |
Evidence on the benefits (both clinical outcomes and serological studies) in people with ARDs on different medications, including the impact of off-label dosing on effectiveness | May help inform decisions regarding whether to hold medications around the time of vaccination and recommendations on optimal dosing intervals for 2-dose vaccines |
Evidence on patient values preferences for the benefits and harms across different patient populations | Will help inform the relative importance of the outcomes |
Understanding vaccine hesitancy and barriers to vaccine access faced by persons with ARDs | Will help inform strategies to address vaccine hesitancy |
Understanding vaccine benefits and harms in populations at risk for inequities | Will help inform strategies to address inequity in vaccine access and uptake |
AE: adverse event; ARD: autoimmune rheumatic disease; COVID-19: coronavirus disease 2019.